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FACTORS INFLUENCING THE DECISION TO
TREAT SERUM LIPID DISORDERS BY DRUG
THERAPY IN THE PRIMARY CARE VENUE
Yuan Y, Silbert G, Doyle J, Copeland K
IMS America, Plymouth Meeting, PA USA
OBJECTIVE: To identify risk factors associated with the
decision to prescribe drug therapy within the first year of
diagnosis.
METHODS: Selected all patients diagnosed with hyper-
cholesterolemia/hyperlipidemia before October 1996 (so
that patients are followed for one year) and who had se-
rum lipid levels recorded prior to initial diagnosis from a
electronic medical records database. Logistic regression
analysis was the tool employed to evaluate the following
factors: age, gender, serum lipid levels and comorbidities
(hypertension, diabetes, coronary heart disease, obesity,
and tobacco use disorder as a surrogate for smoking),
and various combinations.
RESULTS: The total number of patients included in the
analysis was 3,177, with 34.6% prescribed therapy
within one year of diagnosis. For initial therapy, 79.6%
were treated with statins, 6.0% with sequestrants, 10.1 %
with gemfibrozil, and 4.3% with niacin. Among those
treated, 92.9% remained on therapies within the class of
their initial treatment. Age, diabetes, HDL < 35 mg/dL,
LDL ~ 190 mg/dL, CHD and LDL > 130 mg/dL, no
CHD and either fewer than two risk factors with LDL ~
190 or with two or more risk factors and LDL ~ 160
were positively associated with, and presence of tobacco
use disorder was negatively associated with the decision
to prescribe drug therapy within the first year (p = 0.05).
CONCLUSIONS: A range of factors influence prescrip-
tion of antilipemic therapy during the first year after di-
agnosis. This decision has implications for resources de-
voted to patient management during the first year.
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AN ANALYSIS OF THE ECONOMICS OF
HYPERTENSION
West DSI, Corey R2
'University of Mississippi, Oxford, MS, USA; 2Novartis
Phanrnaceuticals Corporation, East Hanover, NJ, USA
Given the economic burden of hypertension and its con-
sequences (i.e., $259 billion in the United States per year),
it is important to identify effective treatment strategies
that use limited medical resources. Thus, economic stud-
ies are continually being conducted in order to provide
clinicians with information on cost-effective management
of hypertension. The purpose of this analysis was to eval-
uate economic studies in hypertension management and
to recommend suggestions for future research.
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METHODS: An extensive review of the literature per-
taining to the economics of hypertension was completed.
Each study was then evaluated, and the methodologies
and results were compared. The studies were also com-
pared to the JNC-VI guidelines.
RESULTS: First, few long-term economic evaluations are
available to aid in determining the most efficient and ef-
fective strategies for managing hypertension in individual
patients or patient groups. Second, the economic analyses
of hypertension are difficult to compare since their meth-
odologies varied widely. In general, they focused on ini-
tial monotherapy, and many of the assumptions regard-
ing treatment were questionable. The studies did not
include all the variables the JNC-VI guidelines refer to
when making therapy decisions.
CONCLUSIONS: Additional economic evaluations that
use a consistent methodology and that include all vari-
ables shown to affect cost-effectiveness ratios, including
the ones considered in developing the JNC-VI guidelines,
are necessary. In addition, economic evaluations of com-
bination products and changes in initial therapy are neces-
sary since these affect the total cost of hypertension treat-
ment. Other considerations for future evaluations (e.g.,
compliance issues, quality of life issues) are reviewed.
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HOW DOES GENDER AFFECT
PHARMACOTHERAPY TREATMENT
DECISIONS FOR HYPERCHOLESTEROLEMIA!
HYPERLIPIDEMIA?
Copeland K, Yuan Y
IMS America, Plymouth Meeting, PA USA
OBJECTIVE: To compare the rate of drug therapy initia-
tion, and the time to treatment for men and women diag-
nosed with lipid disorders.
METHODS: From an electronic medical records database
extracted from primary care doctors' systems, patients
newly diagnosed with hypercholesterolemia/hyperlipi-
demia from October 1, 1993 through September 30, 1996
were selected. Patients were followed through September
30, 1997 resulting in a follow-up time of one to four years.
Patients must have blood cholesterol readings recorded
prior to initial diagnosis. Kaplan-Meier estimation and
Cox regression were used for the analysis. Risk factors
considered include age, estrogen replacement therapy, se-
rum lipid levels, and comorbidities (hypertension, diabetes,
CHD, obesity, and tobacco abuse disorder).
RESULTS: A total of 2,692 patients was included in the
analysis, with 1,223 male and 1,469 female. Among these
patients, 33.4% of the males and 34.5% of the females (p
= 0.58) were prescribed drug therapy within a year of di-
agnosis. Time to treatment between males and females
was not significantly different (Log-rank test, p = 0.83).
Gender was not a significant predictor when controlling
for other risk factors (Cox regression, p = 0.91). For pa-
tients in the two highest risk groups according to Na-
tional Cholesterol Education Program (NCEP) guidelines,
